Safety Profile of Nulojix in Home Infusion Settings

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Nulojix

Study type: Observational

Funder types: Industry

Identifiers

NCT02500498

IM103-370

Details and patient eligibility

About

The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit. Infusion related adverse events are quantified as number of patients with adverse event over the total number of patients and number of event over total number of home infusion visits.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All adult kidney-only transplant recipients currently receiving NULOJIX in BiologicTx home infusion service settings